- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05038462
Fosterhjernepleje: Terapier til hjernens neuroudvikling i fostervækstbegrænsning
Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Randomized controlled trial among pregnant women that have been diagnosed of fetal growth restriction. These women will be randomized in order to evaluate the impact of maternal supplementation with Lactoferrin and DHA on the neurodevelopment outcome of their babies.
Main hypothesis: a prenatal intervention based on maternal supplementation with Lactoferrin and DHA improves neurodevelopment in fetal growth restriction.
Secondary hypothesis are that a prenatal intervention based on maternal supplementation with Lactoferrin and DHA in fetal growth restriction improves fetal growth and improves perinatal morbidity and mortality.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Elisenda Eixarch, MD; PhD
- Telefonnummer: 0034 932279333
- E-mail: eixarch@clinic.cat
Undersøgelse Kontakt Backup
- Navn: Elena Monterde, MD
- Telefonnummer: 0034 932279333
- E-mail: monterde@clinic.cat
Studiesteder
-
-
-
Barcelona, Spanien
- Rekruttering
- Hospital Dexeus-Quirón
-
Kontakt:
- Gerard Albaigés
-
Barcelona, Spanien
- Rekruttering
- Hospital Clínic de Barcelona
-
Kontakt:
- Elisenda Eixarch
- E-mail: eixarch@clinic.cat
-
Underforsker:
- Elena Monterde
-
Barcelona, Spanien
- Rekruttering
- Hospital del Mar
-
Kontakt:
- Elena Ferriols
-
Barcelona, Spanien
- Rekruttering
- Hospital de la Santa Creu i Sant Pau
-
Kontakt:
- Pablo García-Manau
-
Esplugues de Llobregat, Spanien
- Rekruttering
- Hospital Sant Joan de Déu
-
Kontakt:
- Míriam Illa
- E-mail: milla@sjdhospitalbarcelona.org
-
L'Hospitalet de Llobregat, Spanien
- Rekruttering
- Hospital General del Hospitalet
-
Kontakt:
- Susana Fernández
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Singleton pregnancies
- Non-malformed fetus
- Pregnancies with fetal growth restriction
- 24-32.6 weeks of gestation
Exclusion Criteria:
- Chromosomal or structural abnormalities diagnosed during pregnancy or in the neonatal period
- Critical Doppler study suggesting the need for delivery within the next 14 days at the time of diagnosis: reverse end-diastolic velocity in the umbilical artery or ductus venosus pulsatility >95th centile
- Maternal mental or psychiatric disorders
- Maternal allergy to cow's milk protein
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Maternal supplementation with Lactoferrin and DHA
The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily |
The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily |
|
Placebo komparator: Placebo
Product with the same physical appearance and taste as the main intervention but without therapeutic effect |
Product with the same physical appearance and taste as the main intervention but without therapeutic effect |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Bayley III scale at 24 months of age
Tidsramme: 24 months of corrected postnatal age
|
Bayley III scale is and individually administered instrument that assesses infant development across five domains, including cognitive, language and motor competencies. Parent reported questionnaires are incorporated to assess social-emotional and adaptative behaviors. |
24 months of corrected postnatal age
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cortical development
Tidsramme: 34 weeks of gestation
|
Assessed by fetal brain magnetic resonance imaging. |
34 weeks of gestation
|
|
Fetal brain volume
Tidsramme: 34 weeks of gestation
|
Assessed by fetal brain magnetic resonance imaging. |
34 weeks of gestation
|
|
Corpus callosum area
Tidsramme: Enrolment, 32 and 36 weeks of gestation
|
Assessed by fetal neurosonography. |
Enrolment, 32 and 36 weeks of gestation
|
|
Neonatal weight
Tidsramme: Delivery
|
Birth weight |
Delivery
|
|
Perinatal morbidity and mortality
Tidsramme: Perinatal period: period ranging from 32 weeks of gestation (154 days) to the end of the first 4 weeks of neonatal life (28 days)
|
Development of one of the following conditions: pregnancy complications, perinatal mortality, metabolic acidosis and major neonatal morbidity. |
Perinatal period: period ranging from 32 weeks of gestation (154 days) to the end of the first 4 weeks of neonatal life (28 days)
|
|
Postnatal neurodevelopmental assessment
Tidsramme: Between 4 and 24 months of corrected postnatal age
|
Neurodevelopmental assessment using the Bayley III scale at 6 and 24 months of corrected postnatal age, as described in the primary outcome. A complementary neurodevelopmental assessment will be carried out in collaboration with the Speech Acquisition and Perception Groups of the University Pompeu Fabra Barcelona. |
Between 4 and 24 months of corrected postnatal age
|
|
Occurrence of adverse effects
Tidsramme: Through intervention (supplementation) completion, from enrolment to delivery
|
Record of side effects that may appear. Since intervention is usually well tolerated, we do not expect major side effects. |
Through intervention (supplementation) completion, from enrolment to delivery
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Patologiske processer
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Graviditetskomplikationer
- Fostersygdomme
- Vækstforstyrrelser
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Fostervæksthæmning
- Aminosyrer, peptider og proteiner
- Proteiner
- Kulhydrater
- Hydrolaser
- Enzymer
- Enzymer og coenzymer
- Globuliner
- Glycoproteiner
- Glycoconjugates
- Endopeptidaser
- Peptidhydrolaser
- Serinendopeptidaser
- Serinproteaser
- Diætproteiner
- Mælkeproteiner
- Animalproteiner, kost
- Bærerproteiner
- Transferrins
- Jernbindende proteiner
- Lactoglobuliner
- Valleproteiner
- Metalloproteiner
- Lactoferrin
Andre undersøgelses-id-numre
- Fetal Brain Care
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .